Late Breaking Abstract - Biofilm formation by Pseudomonas aeruginosa in empyema

J. Liang (Nan ning, China), Z. Zhang (Nan ning, China), J. Li (Nan ning, China), J. Kong (Nan ning, China), W. Ke (Nan ning, China)

Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Session: Antibiotic therapy for pneumonia and pleural infections
Session type: Oral Presentation
Number: 4666
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Liang (Nan ning, China), Z. Zhang (Nan ning, China), J. Li (Nan ning, China), J. Kong (Nan ning, China), W. Ke (Nan ning, China). Late Breaking Abstract - Biofilm formation by Pseudomonas aeruginosa in empyema. 4666

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy of Ceftolozane/Tazobactam in Comparison with Piperacillin/Tazobactam in Severe Pseudomonas aeruginosa Pneumonia Swine Model
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019


Pseudomonas aeruginosa pneumonia in the community
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014


Should pseudomonas aeruginosa be the main target in bronchiectasis?
Source: International Congress 2016 – Monitoring comorbidities
Year: 2016


Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors?
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016


Bayer Expert Forum at ERS 2014 ‘Infection, Exacerbation and Colonisation: Managing Pseudomonas aeruginosa in non-CF Bronchiectasis’ – Full Video
Source: International Congress 2014 – Bayer Expert Forum at ERS 2014 ‘Infection, Exacerbation and Colonisation: Managing Pseudomonas aeruginosa in non-CF Bronchiectasis’ – Full Video
Year: 2014

Pseudomonas aeruginosa colonisation in patients without bronchiectasis
Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura
Year: 2014

Eradication of Pseudomonas aeruginosa in cystic fibrosis
Source: Eur Respir J 2006; 27: 438-439
Year: 2006


Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


Pulmonary infections with pseudomonas aeruginosa
Source: Eur Respir J 2004; 24: Suppl. 48, 642s
Year: 2004

Pseudomonas aeruginosa from CF airways uses various strategies to outcompete staphylococcus aureus
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors
Source: Eur Respir J 2010; 35: 598-615
Year: 2010



Variation in hydrogen cyanide production between different strains of Pseudomonas aeruginosa
Source: Eur Respir J 2011; 38: 409-414
Year: 2011



Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty?
Source: Eur Respir J 2010; 35: 473-474
Year: 2010


Molecular mechanisms and virulence of colistin-resistant klebsiella pneumoniae
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016


Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016


Pseudomonas, enterobacteriaceae ESBL positive and staphylococcus MRSA: When to suspect them in CAP?
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients
Source: Eur Respir J 2006; 27: 653
Year: 2006


Respiratory commensal streptococcus spp do not modulate the outcome of pseudomonas aeruginosa infection in vivo
Source: International Congress 2016 – Cystic fibrosis: various aspects
Year: 2016

Antimicrobial activity of N-acetylcysteine against Stenotrophomonas maltophilia and Burkholderia cepacia complex grown in planktonic phase and in biofilm
Source: International Congress 2017 – How can microbiology and translational research help physicians?
Year: 2017


Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre
Source: Eur Respir J 2005; 25: 474-481
Year: 2005